胞磷胆碱联合奥拉西坦治疗急性脑梗死的疗效观察

目的探讨胞磷胆碱联合奥拉西坦治疗急性脑梗死的临床疗效。方法选取2016年1月—2016年12月在濮阳市安阳地区医院进行治疗的急性脑梗死患者82例,随机分为对照组和治疗组,每组各41例。对照组患者静脉注射奥拉西坦注射液,4 g加入生理盐水250 m L,1次/d。治疗组在对照组的基础上口服胞磷胆碱钠胶囊,0.2 g/次,3次/d。两组患者均治疗28 d。观察两组患者临床疗效,比较治疗前后两组患者神经功能缺损评分(NHISS)、日常生活能力量表(ADL)和蒙特利尔认知评估量表(Mo CA)评分以及不良反应情况。结果治疗后,对照组临床总有效率为78.05%,显著低于治疗组患者的90.24%,两组比较差异具有统计学意义(P0.05)。两组NHISS评分均显著降低,Mo CA和ADL评分均显著升高,同组治疗前后比较差异具有统计学意义(P0.05)。治疗后,治疗组患者NHISS评分显著低于对照组,Mo CA和ADL评分显著高于对照组,两组比较差异具有统计学意义(P0.05)。治疗期间,对照组不良反应发生率为4.88%,显著低于治疗组患者的17.07%,两组比较差异具有统计学意义(P0.05)。结论胞磷胆碱胶囊联合奥拉西坦治疗急性脑梗死的临床疗效明显优于单用奥拉西坦,具有一定的临床推广应用价值。

Clinical observation of citicoline combined with oxiracetam in treatment of acute cerebral infarction

Objective To discuss the effect of citicoline combined with oxiracetam in treatment of acute cerebral infarction. Methods Patients (82 cases) with acute cerebral infarction in Anyang District Hospital of Puyang from January 2016 to December 2016 were randomly divided into control and treatment groups, and each group had 41 cases. Patients in the control group were iv administered with Oxiracetam Injection, 4 g added into normal saline 250 mL, once daily. Patients in the treatment group were po administered with Citicoline Sodium Capsules on the basis of the control group, 0.2 g/time, three times daily. Patients in two groups were treated for 28 d. After treatment, the clinical efficacy was evaluated, and the NHISS, MoCA and ADL scores, adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 78.05%, which was significantly lower than 90.24% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, NHISS score in two groups were significantly decreased, but MoCA and ADL scores were significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the NHISS score in the treatment group was significantly lower than that in the control group, but MoCA and ADL scores were significantly higher than that in the control group, with significant difference between two groups (P < 0.05). During the treatment, the incidence of adverse reactions in the control group was 4.88%, which was significantly lower than 17.07% in the treatment group, with significant difference between two groups (P < 0.05). Conclusion The clinical efficacy of citicoline combined with oxiracetam in treatment of acute cerebral infarction is significantly better than oxiracetam, which has a certain clinical application value.